SCHEMBL3616249

SCHEMBL3616249

O=C1Nc2ccccc2Nc2ccc(F)cc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 5/20 0.64
ACVR1 Q04771 2/20 0.64
ROS1 P08922 1/20 0.64
CDK5 Q00535 1/20 0.64
PDGFRA P16234 1/20 0.62
FER P16591 1/20 0.62
LTK P29376 1/20 0.62
CDK8 P49336 1/20 0.62
DYRK1B Q9Y463 1/20 0.62
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
CSNK1G1 Q9HCP0 1/20 0.56
CHEK1 O14757 1/20 0.56
FLT3 P36888 3/20 0.52
EGFR P00533 2/20 0.50
BACE1 P56817 1/20 0.49
AGTR1 P30556 1/20 0.49
KDR P35968 1/20 0.49
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17993494 0.90 LRRK2 (0.54) LRRK2ACVR1ROS1CDK5KMT2A
SCHEMBL3409341 0.89 LRRK2 (0.69) LRRK2ACVR1ROS1CDK5PDGFRA
SCHEMBL16712562 0.85 ACVR1 (0.62) LRRK2ACVR1ROS1CDK5PDGFRA
SCHEMBL20442466 0.83 CHEK1 (0.67) LRRK2ACVR1ROS1CDK5PDGFRA
SCHEMBL11890574 0.82 FLT3 (0.54) LRRK2ACVR1ROS1CDK5PDGFRA
SCHEMBL11029136 0.82 FLT3 (0.54) LRRK2ACVR1ROS1CDK5PDGFRA
5-Fluoroisatin SCHEMBL7829877 0.82 MAOB (0.69) LRRK2KMT2AMEN1FLT3AGTR1
SCHEMBL11482314 0.82 LRRK2 (0.48) LRRK2ACVR1ROS1CDK5PDGFRA
SCHEMBL9176425 0.79 CYP1A2 (0.56) LRRK2ACVR1ROS1CDK5FER
SCHEMBL7496945 0.79 CHEK1 (0.44) LRRK2ACVR1ROS1CDK5PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587029-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES Invea Therapeutics, Inc. (US) 2025-07-23 EP claimed
WO-2024059085-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES INVEA THERAPEUTICS, INC. (US) 2024-03-21 WO claimed
US-8202989-B2 One step process for the preparation of substituted 5, 10-dihydrodibenzo [b,e][1, 4]diazepine-11-ones COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-06-19 US claimed
US-20100228023-A1 ONE STEP PROCESS FOR THE PREPARATION OF SUBSTITUTED 5, 10-DIHYDRODIBENZO [b,e][1, 4]DIAZEPINE-11-ONES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-09-09 US claimed
US-20250206714-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES INVEA THERAPEUTICS, INC. 2025-06-26 US disclosed
US-8202989-B2 One step process for the preparation of substituted 5, 10-dihydrodibenzo [b,e][1, 4]diazepine-11-ones COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-06-19 US disclosed
US-20100228023-A1 ONE STEP PROCESS FOR THE PREPARATION OF SUBSTITUTED 5, 10-DIHYDRODIBENZO [b,e][1, 4]DIAZEPINE-11-ONES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228023-A1 ONE STEP PROCESS FOR THE PREPARATION OF SUBSTITUTED 5, 10-DIHYDRODIBENZO [b,e][1, 4]DIAZEPINE-11-ONES BBOX1, CYP1B1, CYP4B1 LRRK2 4616/4885ACVR1 949/4885ROS1 2526/4885
US-20250206714-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES PYCARD, NOD2, CASP1 LRRK2 161/4885ACVR1 4434/4885ROS1 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.